sb-728-t
Cell therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 2, 2018 (NCT03666871)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, passive
Human immunodeficiency virus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03666871 | Phase 1/Phase 2 (Phase 2) | Dec 2, 2018 | Case Western Reserve University, University of California, San Francisco, University of Cincinnati |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Case Western Reserve University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Cincinnati | Academic/Hospital | 1 | 1 | 1 | 2018 |
3 organizations
Page 1 / 1